Cetirizine Dihydrochloride prices in the U.S. are expected to decline by the end of September 2025, influenced by trade policies, stockpiling behaviors, and regulatory pressures on pharmaceutical pricing. Despite recent tariff tensions between the U.S. and India, exemptions on pharmaceuticals and strategic industry responses are helping stabilize supply and support price reductions.
Key Highlights
-
President Trump’s xxx tariffs on India took effect on August xx, but pharmaceuticals were exempted.
-
Indian pharmaceutical exporters remain critical, supplying nearly xxx of U.S. generic drug demand.
-
U.S. buyers pre-stocked medicines anticipating tariffs, ensuring sufficient Cetirizine Dihydrochloride supply currently.
-
Trump urged xx drugmakers to lower U.S. drug prices by September xx, including offering Medicaid patients the lowest prices available in developed countries.
-
Earlier threats of up to xxxx tariffs on pharmaceutical imports raised concerns about price hikes and shortages.
-
Transitioning API and drug production away from India would take x–x years, underscoring current supply chain reliance.
At the demand side, certain U.S. purchasers hoarded prior to tariffs taking effect, easing short-term pressure on prices of Cetirizine Dihydrochloride. The exception of the pharmaceutical tariff permitted uninterrupted flow from India, avoiding abrupt cost escalation of Cetirizine Dihydrochloride. Concurrently, President Trump&#xx;s request to drug companies to lower prices by the...
